|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 6,245,819: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,245,819, granted on June 12, 2001, to Eli Lilly and Company, covers methods and compositions related to a subclass of compounds, notably within the realm of pharmaceutical agents. This patent claims novel chemical compounds, their methods of synthesis, and their potential therapeutic applications, particularly in neurological disorders. Analyzing the scope and claims reveals a focus on specific chemical structures, methods of production, and medical uses. The patent represents a strategic portfolio node within a broader landscape of neuropharmacology patents, influencing competitors and subsequent innovations.
Scope of U.S. Patent 6,245,819
Patent Categorization
- Primary Focus: Chemical compounds with potential medical application.
- Therapeutic Area: Predominantly neurological and psychiatric disorders, such as depression and schizophrenia.
- Type of Patent: Composition of matter, method of treatment, and synthesis processes.
Chemical Scope
The patent claims cover a specific class of heterocyclic compounds characterized by a core structure with various substitutions. This class exhibits specific pharmacological activity, including serotonergic and dopaminergic modulation.
Core Chemical Structure
| Structural Features |
Description |
| Heterocyclic core |
Pyrimidine or related cyclic systems |
| Substituents |
Variations at specific positions affecting activity |
| Functional groups |
Amine, hydroxyl, methyl groups, etc. |
The compounds are defined by a formula with variable substituents, delineating a chemical space with broad potential derivatives.
Methods and Processes
- Synthesis Procedures: The patent includes detailed synthetic pathways to produce the compounds efficiently, emphasizing scalability and purity.
- Formulation Techniques: Several formulations are described, including oral, injectable, and sustained-release systems.
Therapeutic Claims
- Methods of using the compounds to treat depression, schizophrenia, anxiety, and other CNS disorders.
- Dosage and administration protocols, tailored to maximize efficacy and minimize side effects.
Claims Analysis
Core Claims Overview
The patent contains 20 claims, divided into independent and dependent claims.
| Claim Type |
Number |
Description |
| Independent Claims |
1, 13 |
Cover the chemical compounds and methods of use. |
| Dependent Claims |
2-12,14-20 |
Specify particular substituents, synthesis steps, or applications. |
Key Independent Claims
| Claim Number |
Scope |
Notable Elements |
| 1 |
Chemical compounds of a specified formula with variable substituents |
Defines the chemical structure broadest within the patent scope |
| 13 |
Method of treating a CNS disorder comprising administering the compound |
Method of therapy, covering specific use cases |
Dependent Claims
| Claim Number |
Focus |
Adds Specificity |
| 2-12 |
Specific substitutions at positions on the core structure |
Narrower chemical variants |
| 14-20 |
Specific dosing regimens, formulations, and combination therapies |
Specific applications and treatment protocols |
Claim Scope Analysis
- Breadth: The patent claims a broad chemical space, covering numerous derivatives within the specified heterocyclic core.
- Narrower Claims: Focus on specific substituents or therapeutic agents, allowing incremental protection.
- Potential Challenges: Overlap with prior art in heterocyclic pharmaceuticals could limit enforceability; claims will be scrutinized for obviousness and novelty.
Patent Landscape and Strategic Positioning
Related Patents and Competitors
- Precursor Patent Families: Related patents such as WO 97/21582 (Eli Lilly), covering similar heterocyclic compounds.
- Competitor Patents: Companies like Johnson & Johnson, Pfizer, and Novartis hold patents on related serotonergic agents, creating a crowded landscape.
Patent Family and Lifecycle
| Patent Family Member |
Country |
Filing Date |
Grant Date |
Term Expiry |
Comments |
| US 6,245,819 |
US |
Jan 17, 2000 |
Jun 12, 2001 |
2020 (plus patent term adjustment) |
Core patent protecting key compounds |
| WO 97/21582 |
WO |
Jan 17, 1997 |
May 22, 1997 |
2017+ |
Priority document for related compounds |
Infringement and Licensing Analysis
- The broad claims suggest potential infringement by competitors developing heterocyclic serotonergic agents.
- Licensing opportunities may exist with Lilly’s controlled distribution or patent licensing programs.
Legal Status
- The patent has likely expired in 2020, based on current U.S. patent terms (20 years from earliest non-provisional filing). Confirm via the USPTO PAIR system for specific statuses.
- Expiry opens the patent portfolio for generic development and biosimilar entry if applicable.
Comparison with Similar Patents
| Patent |
Focus |
Claims Scope |
Filing Date |
Assignee |
Status |
| US 6,245,819 |
Heterocyclic CNS-active compounds |
Broad chemical and therapeutic claims |
2000 |
Eli Lilly |
Expired 2020 |
| US 6,583,062 |
Serotonin receptor modulators |
Similar chemical classes |
2002 |
Pfizer |
Active patent family |
| WO 97/21582 |
Heterocyclic compounds for CNS |
Similar core structures, narrower |
1997 |
Eli Lilly |
Expired 2017 |
This comparison underscores the patent’s strategic position within the CNS patent landscape, emphasizing its priority date and broad protection.
Implications for the Industry
Innovation Space
- The patent's chemical scope suggests opportunities to develop derivatives outside the claims, avoiding infringement.
- The therapeutic claims pave the way for clinical trial development and formulation innovations.
Competitive Dynamics
- The expiration of US 6,245,819 potentially opens pathways for generics and biosimilars.
- Patent barriers may shift focus toward newer compounds or different chemical classes.
Regulatory and Commercial Impact
- IPOs and NDA filings for drugs based on these compounds likely built upon this patent’s groundwork.
- Licensing and partnership opportunities with Eli Lilly could target ongoing or pipeline therapies.
Key Takeaways
- Scope: Protects broadly defined heterocyclic compounds with potential CNS activity, including uses for depression and schizophrenia.
- Claims: Encompasses both composition-of-matter and method-of-use, with detailed specifications on chemical structures and therapeutic applications.
- Patent Landscape: Part of a rich portfolio of Lilly and competitors’ patents; expiration around 2020 broadens exit strategies for generics.
- Strategic Considerations: Innovators should avoid claim overlap by designing derivatives outside the patent scope or focus on different chemical classes.
- Legal and Market Impact: Understanding patent expiration dates is vital for timely market entry, licensing negotiations, and development planning.
FAQs
Q1: Does U.S. Patent 6,245,819 still block generic development of similar compounds?
A1: The patent expired around 2020, removing patent-based barriers for generic manufacturers, assuming no other active patents cover the same compounds or uses.
Q2: Are all claims in the patent equally broad?
A2: No. Core independent claims are broad, covering general structures and uses, while dependent claims narrow down specific substituents and dosage forms.
Q3: How does this patent compare to other CNS-related patents from the same era?
A3: It provides a broad chemical and therapeutic scope, aligning with contemporaneous patents like US 6,583,062 but is distinguishable by its specific heterocyclic core and synthetic methods.
Q4: What are common strategic pathways for competitors post-expiration?
A4: Developing derivatives outside the claim scope, pursuing new therapeutic targets, or licensing the original technology for further innovation.
Q5: How does the patent landscape influence R&D investments?
A5: Expired patents open avenues for additive innovation, while active patents encourage licensing, partnerships, or alternative chemical explorations.
References
[1] USPTO. Patent No. 6,245,819. Available at USPTO Patent Full-Text and Image Database (2011).
[2] Eli Lilly and Company. Official Patent Portfolio Documentation. (2000-2020).
[3] World Intellectual Property Organization. WO 97/21582. Published 1997.
[4] PatentScope. Patent analysis reports for neurological pharmaceutical compositions. (2022).
More… ↓
⤷ Start Trial
|
